This trial is evaluating whether Cognitive Training will improve 1 primary outcome, 1 secondary outcome, and 1 other outcome in patients with Caregivers of People With Alzheimer's Disease or Related Dementia (ADRD). Measurement will happen over the course of Three years.
This trial requires 7600 total participants across 2 different treatment groups
This trial involves 2 different treatments. Cognitive Training is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Not only are dementia and Alzheimer's disease common, they are potentially preventable and treatable. Although more than 99.9% of people over age 85 have at least some degree of cognitive impairment, we have found that about 20 to 40% of these patients will have Alzheimer's disease. Because dementia can change the lifestyle of an individual and increase their risk of falls, early detection and treatment is crucial to avoiding any permanent damage. Power makes it easy to find dementia clinical trials tailored to your condition, treatment, or location." - Anonymous Online Contributor
"This article deals with an exciting question. Given that, in the year 2000, the population in the United States of America is expected to exceed 114 million and the incidence of Alzheimer's disease is expected to reach 7,000 cases per year, it looks like an attractive idea to evaluate the feasibility of a cure for Alzheimer's disease and, at the same time, assess the risks of such therapeutical innovation. The article discusses how such a goal may be reached and what would need to be considered in making specific statements about how to treat Alzheimer's disease." - Anonymous Online Contributor
"Some signs of Alzheimer disease include confusion and a gradual loss of memory. As the disease progresses, symptoms such as hallucinations and delusions may begin to appear. Other signs of Alzheimer disease include lack of appetite, weight loss and trouble talking.\n" - Anonymous Online Contributor
"Although the prevalence of AD in the United States was estimated at 1.3 percent of the entire adult population, Alzheimer's disease imposes a major economic burden in terms of expenditures on health care services and long-term institutional care for seniors. The estimated number of AD patients in the United States has been increasing; from 1970 to 1992, the number of documented AD patients increased from 5.7 million to 33.5 million." - Anonymous Online Contributor
"Alzheimer's disease is caused by the abnormal accumulation of beta amyloid, the peptide precursor to amyloid beta, a neurotoxic product of the brain. The hallmark symptoms of Alzheimer's disease are impaired memory; difficulty with planning, problem solving, and multitasking; and problems with visuospatial ability; and thinking that loses focus and become tangential. It is an age-related brain disease that typically affects people in their 70s and 80s. Roughly 2% of the population are affected with Alzheimer's disease." - Anonymous Online Contributor
"A minority of patients do not wish to be involved in treatment decisions. Cognitive-behavioural therapy (CBT) can be effective in reducing some of the difficulties that patients experience in taking medication. Medications used to treat neuroleptic-induced physical side effects are not helpful unless they are necessary.\n\nc-fos kinase\n\nlaser therapy\n\nThis is a list of terms for medicines and other treatments for schizophrenia and bipolar disorder. There are no FDA approved medications currently for these indications, but medications (as with any form of treatment) are available and used to treat these conditions.\n\nThere are medications prescribed specifically for schizophrenia." - Anonymous Online Contributor
"Results from a recent paper demonstrate that, when training for and performing a cognitive task, older adults are generally less aware of side effects to their performance. Many of these side effects are common for older adults that may have a negative influence on treatment success. Further research is needed to determine if side effects could be avoided through more targeted intervention or through the use of pharmacological treatments, such as the use of a stimulant drug, for these participants that are at a high risk of developing cognitive deterioration." - Anonymous Online Contributor
"These data suggest that clinicians should offer cognitive training to patients with mild-to-moderate AD to improve their functioning, but not to patients with severe AD or patients who present with severe comorbidities." - Anonymous Online Contributor
"When a patient attends to their primary care provider, they typically do not learn much about what causes Alzheimer's disease. The medical specialty is the best source of information for patients seeking to learn more about what causes disease. To help patients understand what causes Alzheimer's disease, physicians or other professionals should always tell patients what other causes may be there. If the patient also wants to learn what causes Alzheimer's disease, then the psychiatrist will be the best source of information. Psychiatric patients often require medication, and the doctor prescribing medication knows more than most medical patients about causes of the disease. The patient or family member should see the psychiatrists often because the patient may only learn about Alzheimer's disease from the psychiatrists." - Anonymous Online Contributor
"Cognitive training improves multiple domains of cognition, including memory and attention, irrespective of disease severity. The improvements with cognitive training were associated with improvements in executive function, attention, and working memory, independent of treatment type. Clinicians and researchers have recently expanded the number of cognitive training interventions to include tasks aimed at increasing the efficiency of working memory processes to support memory formation and retrieval. Although the mechanisms by which treatment-driven improvements are produced are incompletely understood, these findings support the growing research literature showing the potential for cognitive training to reduce the burden of dementia and to contribute to maintaining and improving the general wellness of individuals with AD. [Power(https://www.withpower." - Anonymous Online Contributor
"New research has demonstrated the validity and efficacy of cognitive training with the aim of improving cognitive performance. This research has highlighted the potential of cognitive training as a promising therapy for the treatment of AD in early stages of disease." - Anonymous Online Contributor
"Results from a recent clinical trial of cognitive training trials are varied. There need to be more high-quality trials, and the heterogeneity in designs of the trials as well as varying outcomes of the training programs make it difficult to draw conclusions on the efficacy of intervention in enhancing neurocognitive functions for people with Alzheimer's disease and related dementias." - Anonymous Online Contributor